Bolt Biotherapeutics (NASDAQ:BOLT) Trading Down 4.5%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell 4.5% on Friday . The stock traded as low as $17.34 and last traded at $18.33. 4,377 shares were traded during mid-day trading, a decline of 98% from the average session volume of 259,291 shares. The stock had previously closed at $19.19.

Several brokerages have weighed in on BOLT. Guggenheim began coverage on Bolt Biotherapeutics in a report on Monday, March 8th. They issued a “buy” rating and a $42.00 price target for the company. Stifel Nicolaus began coverage on Bolt Biotherapeutics in a report on Monday, March 8th. They issued a “buy” rating and a $40.00 price target for the company. SVB Leerink raised their price target on Bolt Biotherapeutics from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, April 13th. Finally, Morgan Stanley began coverage on Bolt Biotherapeutics in a report on Monday, March 8th. They issued an “overweight” rating and a $45.00 price target for the company.

The firm has a fifty day moving average price of $24.82.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Tuesday, March 30th. The company reported ($14.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.80) by ($12.78).

Several institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. purchased a new position in Bolt Biotherapeutics during the first quarter valued at approximately $28,000. Strs Ohio purchased a new position in Bolt Biotherapeutics during the first quarter valued at approximately $102,000. Rokos Capital Management LLP purchased a new position in Bolt Biotherapeutics during the first quarter valued at approximately $149,000. The Manufacturers Life Insurance Company purchased a new position in Bolt Biotherapeutics during the first quarter valued at approximately $240,000. Finally, American International Group Inc. purchased a new position in Bolt Biotherapeutics during the first quarter valued at approximately $243,000.

Bolt Biotherapeutics Company Profile (NASDAQ:BOLT)

Bolt Biotherapeutics, Inc, a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers.

Recommended Story: Neutral Rating

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.